Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.
Also called NCT02589639
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 269 participants
- Registry
-
NCT02589639
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02589639. Randomized; no masking; primary purpose treatment. Start 2015-10-28 (actual); primary completion 2017-04-18 (actual). Results posted on 2019-03-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02589639- Content hash
9ceb7e7a9732aa45681ccfb35ba464424fde8e75f2a316ddf785b2e90196d957